Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Why Is Pacific Biosciences of California (PACB) Stock Up +16.33% Today?

Why Is Pacific Biosciences of California (PACB) Stock Up +16.33% Today?

Key Takeaways

  • PACB shares surged 16.33% to about $2.85, extending a powerful multi-week rally driven by a wave of artificial-intelligence and genomics partnerships.
  • The primary catalyst is sustained momentum from strategic collaborations — including a multi-year deal with Verily Health and an AI drug-discovery pact with TychoBio — that position PacBio's HiFi long-read sequencing at the center of biomedical AI.
  • Secondary drivers include a five-year, up to $27.1 million U.S. Department of Veterans Affairs contract announced via genomics provider Sampled, and a Stephens analyst price-target raise to $2.50 from $1.50.
  • The stock has been highly volatile and has roughly doubled over the past month, with heavy call-option buying and possible short covering amplifying the move.
  • Traders are watching the company's third-quarter earnings report, scheduled for November 4, 2026, as the next major catalyst.
  • For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
  • To discover AI-driven trading strategies tuned to current market conditions, visit Trending AI Robots.

Opening Summary

Pacific Biosciences of California, Inc. (PACB), commonly known as PacBio, is a Menlo Park, California-based developer of high-accuracy long-read DNA and RNA sequencing systems, including its Revio and Vega platforms and HiFi sequencing technology. In today's session, the stock climbed 16.33%, recently trading around $2.85 versus a prior close of $2.45, confirming a sharp upward move. Markets attributed the advance to continued enthusiasm around PacBio's growing roster of artificial-intelligence and genomics collaborations, which investors see as expanding the company's addressable market well beyond traditional research instruments.

AI and Genomics Partnership Momentum

The strongest driver behind the rally is a string of recent strategic announcements that have repositioned PACB as a key enabler of AI-powered biology. In mid-October, the company unveiled a multi-year collaboration with Verily Health to integrate PacBio HiFi sequencing into Verily's governed data and AI platform, linking long-read genomic data with multimodal health records and AI-ready research workflows. That followed an October pact with TychoBio, under which PacBio will generate full-length RNA data from more than 10,000 samples to train AI models for rare-disease RNA therapeutics.

These deals build on earlier announcements, including the EpiSign METRIC 5-base launch that enables DNA methylation analysis across more than 300 episignature disorders, and Basecamp Research's selection of HiFi sequencing for its Trillion Gene Atlas. Collectively, the agreements reinforce a narrative that PacBio's long-read data is becoming a foundational input for AI drug discovery — a theme that has driven sustained buying interest across the genomics sector.

Government Contract and Analyst Support

Additional catalysts added fuel to the move. Genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support the Million Veteran Program using PacBio Revio systems, underscoring recurring demand from large-scale population-sequencing initiatives. On the analyst front, Stephens raised its price target on PACB to $2.50 from $1.50 while maintaining an Overweight rating, signaling increased conviction in the company's clinical and consumables trajectory even as broader sentiment on the stock remains mixed.

Short Squeeze and Technical Breakout

The magnitude of the move also reflects technical and positioning dynamics. PacBio is a heavily shorted, high-beta small-cap that has recorded numerous single-day moves exceeding 5% over the past year. Unusually heavy call-option buying — at times several hundred percent above average — along with a sharp climb through the 50-day and 200-day moving averages, has created conditions ripe for short covering and momentum chasing. As the stock broke above prior resistance levels and set fresh multi-month highs, forced buying from short sellers likely amplified the upside.

Market Context and Trading Activity

Trading volume has been elevated relative to the norm. The prior session saw roughly 18.7 million shares change hands, well above the stock's typical daily average of around 8 to 11 million shares, indicating strong conviction rather than a low-liquidity drift. The advance has outpaced the broader market, with PACB posting gains of more than 20% over the past week and roughly 40% over the past month, even as concerns about rising Treasury yields have pressured some growth and healthcare names. The move appears idiosyncratic — tied to company-specific catalysts — rather than a broad sector rotation.

What Comes Next for PACB

Attention now turns to PacBio's third-quarter 2026 earnings report, scheduled for November 4, 2026, with management also set to appear at upcoming investor conferences including the UBS Global Healthcare event. Investors will scrutinize consumables pull-through, Revio and Vega placements, and progress on the SPRQ-Nx chemistry transition, against a backdrop of lowered full-year revenue guidance and a cash-flow breakeven target pushed to 2028. While the AI-partnership narrative has driven momentum, risks remain: the company is unprofitable, faces funding headwinds in research markets, and carries a beta above 2.0, making it vulnerable to sharp reversals if sentiment cools or the earnings report disappoints.

Trending AI Robots

Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots spanning thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Only the bots demonstrating the most robust recent performance are curated into the Trending AI Robots section, giving traders a focused view of which automated strategies are adapting best to today's markets. Explore the section to see which AI strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PACB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


PACB sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 109 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for PACB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 74 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

PACB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

PACB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-21.104) is slightly lower than the industry average of (4.142). P/E Ratio (-5.369) is within average values for comparable stocks, (3.291). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalNursingServices

Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
485
Web
https://www.pacb.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.